Day 3 - Workshops and Spotlights Wednesday October 21, 2020

A

B

C

9:30 - 11:00

Spotlight on the Microbiome and Immunology

Part 1: Understanding the Kinetics of Bacteria-Mediated Drug Metabolism of PrEP Drugs

  •  Recent evidence suggests that vaginal microbial communities are associated with increased HIV acquisition risk
  •  Investigating the mechanisms underlying how vaginal bacteria alter PrEP drug levels and HIV infection rates
  • Hypothesizing that variability in PrEP is a result of bacteria mediated drug metabolism

Part 2: Host Immune-Microbial Interactions in Intestinal Inflammation

  •  Inflammatory bowel disease (IBD) is associated with immune dysregulation
  • IBD is also associated with perturbations of gut microbes and their metabolites
  • Microbial metabolites such as secondary bile acids are depleted during intestinal inflammation
  • Only a few microbes have the ability to convert primary to secondary bile acids
  • Restoration of depleted microbial metabolites could mitigate intestinal inflammation

12:00 - 13:30

Developing Microbiome-Based Therapeutics for Infant Diseases

With a global rise in incidences of immune disorders, childhood-onset diabetes and childhood obesity, the causal link between the maternal-infant microbiome and health outcomes provides researchers with a unique window of opportunity for new products and solutions that target the early gut microbiome. Join a leading paediatric clinician and drug developer at this unique pre-conference workshop to get a deep dive into the mechanisms, challenges and opportunities when developing microbiome-targeting therapeutics during the first 1000 days of life.

Attend this workshop to gain expert insights into:

• The role of FMT for IBD in paediatric populations

• Immune-driven mechanisms that help drive infant microbiome modulation with positive health outcomes

• The unique challenges of developing microbiome-targeted therapeutics in vulnerable patient populations

• Efforts into creating preventative health tools across several diseases which have early on-set across infant populations

14:30 - 16:30

Developing Microbiome-Targeting Biomarkers & Therapeutics for Cancer  Treatment and Patient Response

Increased knowledge of the mechanisms underlying the hallmarks of cancer has driven the evolution of cancer therapeutics. More recently, a wealth of scientific evidence has demonstrated the impact of the gut microbiome in modulating response and resistance to existing cancer treatments. Additionally, findings have revealed causal and consequential roles of the microbiome in cancer pathogenesis and progression.

Attend this workshop to gain expert insights into:

• The fundamental mechanistic pathways underpinning the causality of the human microbiome in cancer and consequential effects of cancer therapeutics on microbial dysbiosis

• Recent results from clinical trials that incorporate the microbiome as a measurable endpoint

• New industry investigations from organisations who are leveraging the power of the human microbiome to develop novel therapeutic strategies that improve patient safety and efficacy outcomes

Aida Habtezion
Nikki Klatt

Aida Habtezion MD
Principal Investigator
Stanford University

Nikki Klatt
Associate Professor Paediatrics
University of Miami

Lynn Bry
Nurry Hong
Stacy Kahn1

Lynn Bry MD
Director
Massachusetts Host Microbiome Center

Nurry Hong
CEO
Pareto Bio

Stacy Kahn MD
Attending Physician
Boston Children’s Hospital

Deepak Gopalakrishnan - AstraZeneca
Capture xan
Jonathan Peled

Deepak Gopalakrishnan
Scientist - Microbiome Discovery
AstraZeneca

Xue Liang
Microbiome Scientist
Merck Exploratory Science Center

Jonathan Peled MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center